Posts Tagged 'Avandia recall'

Avandia users file lawsuit in Illinois over heart problems

A group of 94 patients who allege they were injured after using the diabetes drug Avandia have filed a lawsuit in Illinois against its manufacturer, GlaxoSmithKline. Barbara Meier and the other plaintiffs in the Avandia lawsuit allege that suffered heart attacks, congestive heart failure or other cardiovascular injuries after using the drug to treat their diabetes symptoms.

Click here to read more…

Diabetes drug Avandia to be pulled from retail shelves

The diabetes drug Avandia will be pulled from retail pharmacy shelves in November because it poses such a big heart attack risk, the federal government announced Tuesday. When the new program goes into effect on Nov. 18, only certified doctors will be allowed to prescribe the drug, and only to patients who’ve been informed of the risks and who will fill their prescriptions by mail order through specific pharmacies.

Click here to read more…

Evidence of Avandia side effects risk grows after new study

A new study published by the British Medical Journal has found that patients taking Avandia are more likely to suffer congestive heart failure, heart attack and other side effects compared to other diabetes drugs. Avandia was recalled by the European Medicines Agency over safety concerns in September 2010, although it is still available for sale in the U.S.

Click here to read more…

Glaxo Sees $3.5 Billion Charge Related to Avandia Claims, Sales Practices

GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, said it will have fourth-quarter legal costs of 2.2 billion pounds ($3.5 billion) because of a U.S. investigation into sales practices for certain products and product-liability cases related to the Avandia diabetes drug. The company is setting aside additional provisions for the investigation by the U.S. attorney in Colorado into the company’s sales and promotional practices of certain products, London-based Glaxo said in an e-mailed statement today.

Click here to read more…

Avandia Stays on the Market, But For How Long?

After two days of contentious discussion, a federal advisory committee voted on Wednesday to keep the troubled diabetes drug Avandia (rosiglitazone) on the market, but with added restrictions for its use. Experts had expected the 33-member panel to recommend removing the drug altogether, based on evidence that Avandia, prescribed to control blood sugar in patients with Type 2 diabetes, increases risk of heart attack. That is a particularly worrisome side effect in this population, considering that diabetes itself raises the risk of heart disease.

Click here to read more…

Diabetes Drug Maker Hid Test Data on Risks, Files Indicate

In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. But instead of publishing the results, the company spent the next 11 years trying to cover them up, according to documents recently obtained by The New York Times. The company did not post the results on its Web site or submit them to federal drug regulators, as is required in most cases by law.

Click here to read more…

FDA Mulling End to Avandia-Actos Trial on Safety Worries

The FDA is considering cutting short a trial comparing the safety of two diabetes drugs — GlaxoSmithKline’s Avandia and Takeda’s Actos, the WSJ reports. Given that Avandia has been linked since 2007 to an increased risk of heart attacks, some scientists have said it’s not ethical to put study participants at risk. If the trial is stopped, the FDA will also consider asking Glaxo to stop selling the drug.

Click here to read more…

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 437 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101


Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.